Being prepared for the devastating effects of a significant earthquake on the Hikurangi Subduction will be highlighted at two ...

VYKAT XR was approved by the U.S. Food and Drug Administration (FDA) on March 26, 2025, and is now commercially available to ...

announces four abstract presentations at the AUA 2025, highlighting the benefits of Blue Light Cystoscopy (BLC®), notably its impact on management of the disease, improved risk stratification and ...

Niktimvo (axatilimab-csfr) is a first-in-class colony stimulating factor-1 receptor (CSF-1R)-blocking antibody approved for use in the U.S. for the treatment of chronic graft-versus-host disease (GVHD ...

But the capital market is not a casino, and those who are willing to gamble may not admit defeat. Entrepreneurs, investors, M ...